Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health announced that its gastroenterology business, Salix Pharmaceuticals, will present new data for TRULANCE®, XIFAXAN®, and PLENVU® at the Digestive Disease Week® (DDW) 2021 from May 21-23. Notably, a poster on TRULANCE® has been honored as a Poster of Distinction, awarded to only 10% of the accepted posters. The event emphasizes Salix's commitment to providing healthcare professionals with significant data on their medications to support treatment decisions.
Bausch + Lomb announced the results from the National Eye Institute's 10-Year Follow-on Study of the Age-Related Eye Disease Study 2 (AREDS2), reinforcing the effectiveness of its vitamin formula against moderate to advanced Age-Related Macular Degeneration (AMD). The NEI continues to endorse the PreserVision® AREDS 2 Formula, which contains 80mg of zinc and beneficial amounts of lutein and zeaxanthin. The findings support the importance of this specific nutrient mix for AMD patients, showcasing Bausch + Lomb's commitment to eye health and validated by over 3,800 participants over a decade.
Bausch Health Companies (NYSE/TSX: BHC) announced participation in several investor conferences. Key executives, including CEO Joseph C. Papa, will present at the Bank of America Merrill Lynch Global Healthcare Conference on May 12, 2021, at 11:00 a.m. ET. Other conferences include the Goldman Sachs Leveraged Finance Conference on May 17, 2021, at 1:10 p.m. ET, and the Barclays High Yield Bond and Syndicated Loan Conference on May 25, 2021, at 12:45 p.m. ET. Live webcasts will be available on their Investor Relations page.
Bausch Health Companies reported first-quarter 2021 revenues of $2.027 billion, a 1% increase compared to the previous year, despite a $100 million negative impact from the COVID-19 pandemic. The GAAP net loss was $610 million, worsened by a $469 million goodwill impairment in Ortho Dermatologics. The company generated $443 million in cash from operations, a 70% increase year-over-year. Bausch Health reaffirmed its 2021 guidance, targeting $8.60 – $8.80 billion in revenue and $3.40 – $3.55 billion in adjusted EBITDA.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced a $100 million reduction in debt by redeeming senior secured notes using operational cash. This redemption of $100 million of 7.00% Senior Secured Notes due 2024 will occur on June 2, 2021. In total, the company has redeemed $400 million of these Notes in 2021, following redemptions of $200 million in March and $100 million on May 7. This move reflects Bausch Health's commitment to strengthening its financial position amidst ongoing market challenges.
Bausch + Lomb, a subsidiary of Bausch Health Companies (NYSE: BHC), will present new scientific data at the ARVO annual meeting from May 1-7, 2021. Highlights include one podium and 11 poster presentations on key products, including the investigational drug XIPERE™ and ongoing ARMOR study on antibiotic resistance. The ARMOR study features insights from 2009-2020 on ocular pathogens, while other presentations will cover recent findings from the pharmaceutical and surgical portfolios. This ongoing commitment to research aims to enhance treatment for eye care professionals.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the successful election of 13 nominated directors at its annual meeting on April 27, 2021. Among the elected were Richard U. De Schutter and Sarah B. Kavanagh, receiving over 200 million votes for their positions. Shareholders also approved the compensation of named executive officers in a non-binding advisory vote and appointed PricewaterhouseCoopers LLP as the independent public accounting firm until the 2022 meeting. Full vote details will be reported to the SEC.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has announced the availability of its presentation for the Annual Meeting of Shareholders held on April 27, 2021. This presentation can be accessed via the Investor Relations section of Bausch Health's website. The company focuses on enhancing global health through its diverse healthcare products, including pharmaceuticals and medical devices primarily in eye health, gastroenterology, and dermatology.
Bausch Health Companies (NYSE/TSX: BHC) announced significant topline results from a pivotal Phase 3 trial of IDP-126, a new treatment for acne vulgaris. The trial met all three co-primary endpoints, demonstrating a treatment success rate of 50.5% compared to 20.5% for the vehicle. The study involved 193 participants and showed benefits as early as two weeks. If approved, IDP-126 would be the first-in-class treatment combining retinoid, anti-bacterial, and antibiotic properties. A New Drug Application is anticipated in the second half of 2022.
Bausch Health Companies (NYSE/TSX: BHC) announced six poster presentations at the virtual American Academy of Dermatology (AAD) Annual Meeting, running from April 23-25, 2021. Highlights include new analyses of ARAZLO® (tazarotene) Lotion, focusing on efficacy results from Phase 3 studies for moderate-to-severe acne. Presentations will also cover DUOBRII® (halobetasol propionate and tazarotene) Lotion's effectiveness and quality of life impacts in psoriasis, alongside evaluations of SILIQ® (brodalumab) Injection's long-term efficacy and safety. Scott Hirsch emphasized the commitment to demonstrating clinical benefits.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
